-
Something wrong with this record ?
Pharmacokinetics of acetylcholinesterase reactivator K203 and consequent evaluation of low molecular weight antioxidants/markers of oxidative stress
Jana Žďárová Karasová, Daniela Hnídková, Miroslav Pohanka, Kamil Musílek, Robert Peter Chilcott, Kamil Kuča
Language English Country Czech Republic
NLK
Free Medical Journals
from 2003 to 2013
Freely Accessible Science Journals
from 2003 to 2013
ROAD: Directory of Open Access Scholarly Resources
from 2002
- MeSH
- Antioxidants pharmacokinetics therapeutic use MeSH
- Animal Experimentation MeSH
- Financing, Organized MeSH
- Plasma chemistry MeSH
- Organophosphates antagonists & inhibitors MeSH
- Oxidative Stress drug effects MeSH
- Oximes pharmacokinetics therapeutic use MeSH
- Rats, Wistar MeSH
- Cholinesterase Reactivators pharmacokinetics therapeutic use MeSH
- Statistics as Topic MeSH
- Chromatography, High Pressure Liquid methods utilization MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Animals MeSH
Oxime K203 is a new compound designed to be used as an acetylcholinesterase reactivator for the treatment of intoxication following exposure to tabun and certain pesticides. After intramuscular administration of a therapeutic (23 mg/kg) dose, the time-course of plasma concentrations of K203 in rats was determined by HPLC. Maximum concentrations were reached between 40 and 60 min (16.5±2.1 μg/ml in 40 min and 16.6±2.0 in 60 min, respectively) with the concentration being relatively constant during this period. There was no significant effect on the plasma concentration of thiobarbituric acid reactive substances (TBARS) during the administration of K203, indicating an absence of oxidative stress. Indeed, administration of K203 led to a significant increase in low molecular weight antioxidants which could tentatively be interpreted as representing a beneficial effect.
Center of Advances Studies Faculty of Health Sciences Defence University Hradec Králové
Chemical Hazards and Poisons Division Health Protection Agency Oxfordshire United Kingdom
Department of Chemistry Faculty of Science University of Hradec Králové Hradec Králové
Department of Public Health Faculty of Health Sciences Defence University Hradec Králové
References provided by Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12017061
- 003
- CZ-PrNML
- 005
- 20120725123128.0
- 007
- ta
- 008
- 120601s2012 xr d f 000 0eng||
- 009
- AR
- 024 7_
- $a 10.2478/v10136-011-0015-2 $2 doi
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Žďárová Karasová, Jana, $d 1982- $7 xx0099787 $u Department of Public Health, Faculty of Health Sciences, Defence University, Hradec Králové; University Hospital, Hradec Králové
- 245 10
- $a Pharmacokinetics of acetylcholinesterase reactivator K203 and consequent evaluation of low molecular weight antioxidants/markers of oxidative stress / $c Jana Žďárová Karasová, Daniela Hnídková, Miroslav Pohanka, Kamil Musílek, Robert Peter Chilcott, Kamil Kuča
- 504 __
- $a Literatura $b 35
- 520 9_
- $a Oxime K203 is a new compound designed to be used as an acetylcholinesterase reactivator for the treatment of intoxication following exposure to tabun and certain pesticides. After intramuscular administration of a therapeutic (23 mg/kg) dose, the time-course of plasma concentrations of K203 in rats was determined by HPLC. Maximum concentrations were reached between 40 and 60 min (16.5±2.1 μg/ml in 40 min and 16.6±2.0 in 60 min, respectively) with the concentration being relatively constant during this period. There was no significant effect on the plasma concentration of thiobarbituric acid reactive substances (TBARS) during the administration of K203, indicating an absence of oxidative stress. Indeed, administration of K203 led to a significant increase in low molecular weight antioxidants which could tentatively be interpreted as representing a beneficial effect.
- 650 _2
- $a reaktivátory cholinesterasy $x farmakokinetika $x terapeutické užití $7 D002801
- 650 _2
- $a oximy $x farmakokinetika $x terapeutické užití $7 D010091
- 650 _2
- $a organofosfáty $x antagonisté a inhibitory $7 D010755
- 650 _2
- $a oxidační stres $x účinky léků $7 D018384
- 650 _2
- $a antioxidancia $x farmakokinetika $x terapeutické užití $7 D000975
- 650 _2
- $a vysokoúčinná kapalinová chromatografie $x metody $x využití $7 D002851
- 650 _2
- $a krevní plazma $x chemie $7 D010949
- 650 _2
- $a experimenty na zvířatech $7 D032761
- 650 _2
- $a statistika jako téma $7 D013223
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Hnídková, Daniela. $7 _AN067901 $u Department of Public Health, Faculty of Health Sciences, Defence University, Hradec Králové
- 700 1_
- $a Pohanka, Miroslav $7 hka2010563580 $u University Hospital, Hradec Králové; Center of Advances Studies, Faculty of Health Sciences, Defence University, Hradec Králové
- 700 1_
- $a Musílek, Kamil, $d 1980- $7 xx0135628 $u University Hospital, Hradec Králové; Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradec Králové
- 700 1_
- $a Chilcott, Robert Peter $u Chemical Hazards and Poisons Division, Health Protection Agency, Oxfordshire, United Kingdom
- 700 1_
- $a Kuča, Kamil, $d 1978- $7 xx0041831 $u University Hospital, Hradec Králové; Center of Advances Studies, Faculty of Health Sciences, Defence University, Hradec Králové
- 773 0_
- $t Journal of applied biomedicine $x 1214-021X $g Roč. 10, č. 2 (2012), s. 71-78 $w MED00012667
- 856 41
- $u https://jab.zsf.jcu.cz/pdfs/jab/2012/02/02.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b B 2301 $c 1249 $y 2
- 990 __
- $a 20120601090207 $b ABA008
- 991 __
- $a 20120725123204 $b ABA008
- 999 __
- $a ok $b bmc $g 910933 $s 774224
- BAS __
- $a 3
- BMC __
- $a 2012 $b 10 $c 2 $d 71-78 $i 1214-021X $m Journal of Applied Biomedicine $n J. Appl. Biomed. (Čes. Budějovice Print) $x MED00012667
- LZP __
- $a 2012-29/ipal